DBV Technologies (DBVT) Other financing activities (2020 - 2021)

DBV Technologies (DBVT) posted quarterly Other financing activities of $6000.0 for Q4 2021, up 150.0% year-on-year from $2400.0 in Q4 2020, and up 250.0% on a QoQ basis from -$4000.0 in Q3 2021.

DBV Technologies (DBVT) Other financing activities (2020 - 2021) Analysis & Trends

DBV Technologies (DBVT) has reported Other financing activities for 2 consecutive years, with $6000.0 the latest figure, recorded in Q4 2021.

  • Quarterly Other financing activities rose 150.0% year-over-year to $6000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was $6000.0 (up 118.18% YoY) and the FY2021 annual result came in at -$15000.0, up 58.33% from the prior year.
  • Other financing activities improved to $6000.0 in Q4 2021 per DBVT's latest filing, from -$4000.0 in the prior quarter.
  • Over the last five years, Other financing activities for DBVT reached as high as $6000.0 in Q4 2021 and fell as low as -$17000.0 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 DBV Technologies 267.50 Mn 92.60 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2021 6,000.00
Dec 31, 2021 6,000.00
Sep 30, 2021 -4,000.00
Sep 30, 2021 -4,000.00
Mar 31, 2021 -17,000.00
Mar 31, 2021 -17,000.00
Dec 31, 2020 -12,000.00
Dec 31, 2020 -12,000.00
Sep 30, 2020 -5,000.00
Sep 30, 2020 -5,000.00
Jun 30, 2020 -12,000.00
Jun 30, 2020 -12,000.00
Mar 31, 2020 -7,000.00
Mar 31, 2020 -7,000.00